Arphio, a new business entity dedicated solely to orphan and rare disease medicines
Aztiq and SK Pharma are thrilled to announce the recent establishment of a new entity ArphioTM, a powerhouse, solely dedicated to orphan drugs with the intention of improving access to vital treatments, to patients suffering from rare diseases and with unmet medical needs.
Arphio focuses on rare disease detection, market access and supply of orphan drugs, targeting the EU and ROW regions. The Arphio team has a unique understanding of orphan products and their epidemiology data and unique characteristics. The aim of this venture is to expand access to vital treatments and continue to develop technological capabilities and expertise, while maintaining a patient-centric approach with the possibility of relying on state-of-the art novel technology including worldwide data, artificial intelligence and machine learning.
This stand-alone market player will cover all services and functions ranging from medical, market access, regulatory, direct sales, and marketing activities. Arphio proudly boasts of strictly following ethics, compliance, accessibility, and corporate governance.
There are over 300 million people living with one or more of over 7,000 identified rare diseases around the world, each supported by family, friends, and caregivers. Currently, only about 5% of orphan disorders can be managed with an approved treatment. It is estimated that it takes about seven years and visits to 10 different doctors for a patient to receive a proper diagnostic of an orphan condition. At Arphio, fueled by our passion to improve people’s lives, we will apply innovative technologies to provide effective treatments for people with orphan diseases.
Anil Okay, General Manager at Aztiq comments: “We are thrilled to be partnering with SK Pharma on this exciting new journey. We welcome this opportunity to work in the domain of Orphan drugs, and we are eager to make a valuable contribution to patients across the globe who are living with Rare diseases”.
Dr. Shlomo Sadoun, CEO at SK Pharma comments: “I’m captivated to have Aztiq as our partner with the important endeavor of helping neglected orphan patients and their caregivers with their unmet medical needs. I’m bullish on the synergistical power that could outcome from this collaboration for the benefit of rare disease patients"
Aztiq is one of the leading global B2B pharmaceutical companies, with a declared purpose to make a difference for patients around the world, driven by a smart collaboration network and commitment to deliver the highest quality differentiated products and services to its partners. Aztiq has established itself as a reliable global partner with commercial partnerships in more than 100 countries and with over 110 commercial partners, globally.
Aztiq prides itself on helping its partners reach their goals – whether that’s increasing revenues or pushing into new markets. The company’s purpose driven culture is committed to improving the lives of patients around the world.
The company constantly looks for new ways to delight and deliver and with its fast-moving team Aztiq continually redefines what is possible with a motto of being Always on Target for patients and for partners.
About SK Pharma
SK-Pharma is a global pharmaceutical company focusing on making drugs accessible to patients in needs. The vison of the company lay in utilizing cutting edge technologies to support smart business decisions that will lead to better healthcare solutions. Taking patient centric approach, the company holistically follow the patient’s journey and understand better their unmet needs. Mimicking the patient journey allow us to come with viable solutions that change the patient treatment paradigm and make it more suitable to their lifestyle and their unique needs. The group is divided to three divisions: First to launch and the introduction of complex hybrid generic products. The second division is focusing on providing technological solutions to enhance smart business decisions. The third division is specialized in orphan drugs market access and distribution worldwide.